JP7437301B2 - Ｂ７－ｈ４抗体及びその使用方法 - Google Patents

Ｂ７－ｈ４抗体及びその使用方法 Download PDF

Info

Publication number
JP7437301B2
JP7437301B2 JP2020511358A JP2020511358A JP7437301B2 JP 7437301 B2 JP7437301 B2 JP 7437301B2 JP 2020511358 A JP2020511358 A JP 2020511358A JP 2020511358 A JP2020511358 A JP 2020511358A JP 7437301 B2 JP7437301 B2 JP 7437301B2
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
seq
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020511358A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500853A (ja
JP2021500853A5 (enExample
Inventor
チャールズ カプラン，
デリック ハウザー，
ルイス ボルジェス，
グロリア ブラティッチ，
デイビッド ベロヴィン，
フェリシア ケンプ，
マジッド ゴドゥシ，
ネルス ピー． ニールソン，
キャシー ミラー，
マイク シュミット，
Original Assignee
ファイヴ プライム セラピューティクス インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイヴ プライム セラピューティクス インク filed Critical ファイヴ プライム セラピューティクス インク
Publication of JP2021500853A publication Critical patent/JP2021500853A/ja
Publication of JP2021500853A5 publication Critical patent/JP2021500853A5/ja
Priority to JP2024018525A priority Critical patent/JP2024042117A/ja
Application granted granted Critical
Publication of JP7437301B2 publication Critical patent/JP7437301B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020511358A 2017-08-25 2018-08-23 Ｂ７－ｈ４抗体及びその使用方法 Active JP7437301B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024018525A JP2024042117A (ja) 2017-08-25 2024-02-09 Ｂ７－ｈ４抗体及びその使用方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762550173P 2017-08-25 2017-08-25
US62/550,173 2017-08-25
US201762579774P 2017-10-31 2017-10-31
US62/579,774 2017-10-31
US201762607810P 2017-12-19 2017-12-19
US62/607,810 2017-12-19
US201862656789P 2018-04-12 2018-04-12
US62/656,789 2018-04-12
PCT/US2018/047805 WO2019040780A1 (en) 2017-08-25 2018-08-23 ANTI-B7-H4 ANTIBODIES AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024018525A Division JP2024042117A (ja) 2017-08-25 2024-02-09 Ｂ７－ｈ４抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2021500853A JP2021500853A (ja) 2021-01-14
JP2021500853A5 JP2021500853A5 (enExample) 2021-10-07
JP7437301B2 true JP7437301B2 (ja) 2024-02-22

Family

ID=63490758

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020511358A Active JP7437301B2 (ja) 2017-08-25 2018-08-23 Ｂ７－ｈ４抗体及びその使用方法
JP2024018525A Pending JP2024042117A (ja) 2017-08-25 2024-02-09 Ｂ７－ｈ４抗体及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024018525A Pending JP2024042117A (ja) 2017-08-25 2024-02-09 Ｂ７－ｈ４抗体及びその使用方法

Country Status (21)

Country Link
US (4) US11306144B2 (enExample)
EP (1) EP3672990A1 (enExample)
JP (2) JP7437301B2 (enExample)
KR (2) KR20240138135A (enExample)
CN (2) CN111094352B (enExample)
AU (2) AU2018321902B2 (enExample)
BR (1) BR112020003533A2 (enExample)
CA (1) CA3070774A1 (enExample)
CL (4) CL2020000452A1 (enExample)
CO (1) CO2020001955A2 (enExample)
CR (2) CR20250168A (enExample)
EC (1) ECSP20020111A (enExample)
IL (2) IL321706A (enExample)
MA (1) MA49950A (enExample)
MX (3) MX2020002076A (enExample)
PE (1) PE20200797A1 (enExample)
PH (1) PH12020500368A1 (enExample)
SG (1) SG11202000387YA (enExample)
TW (2) TWI817952B (enExample)
UA (1) UA128472C2 (enExample)
WO (1) WO2019040780A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20200797A1 (es) 2017-08-25 2020-08-10 Five Prime Therapeutics Inc Anticuerpos que se unen especificamente a b7-h4 humana
WO2019136309A1 (en) 2018-01-04 2019-07-11 Iconic Therapeutics, Inc. Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
SG11202007820QA (en) * 2018-02-21 2020-09-29 Five Prime Therapeutics Inc B7-h4 antibody dosing regimens
BR112020016986A2 (pt) 2018-02-21 2021-03-02 Five Prime Therapeutics, Inc. formulações de anticorpo contra b7-h4
CA3091801A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
BR112021007134A2 (pt) * 2018-10-15 2021-08-10 Five Prime Therapeutics, Inc. terapia combinada para câncer
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
US12358985B2 (en) * 2019-03-21 2025-07-15 Suzhou Kanova Biopharmaceutical Co., Ltd. Anti-B7S1 polypeptides and their use
EP3963079A1 (en) * 2019-05-03 2022-03-09 Five Prime Therapeutics, Inc. Pharmaceutical formulations containing cd80 extracellular domain-fc fusion proteins
EP3994150A4 (en) * 2019-07-03 2023-08-02 Iconic Therapeutics LLC ANTI-TISSUE FACTOR-DRUG ANTIBODY CONJUGATES AND RELATED METHODS
CA3166629A1 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
US20230112085A1 (en) * 2020-01-30 2023-04-13 Apeximmune Therapeutics Inc. Anti-b7-h4 constructs and uses thereof
MY210125A (en) 2020-03-18 2025-08-28 Genmab As Antibodies binding to b7h4
MX2022012621A (es) 2020-04-10 2023-01-18 Seagen Inc Enlazadores de variantes de carga.
JP7728595B2 (ja) * 2020-06-30 2025-08-25 ハーバー・バイオメド・ユーエス・インコーポレイテッド 二重特異性抗体及びその用途
JP2023533793A (ja) 2020-07-17 2023-08-04 ファイザー・インク 治療用抗体およびそれらの使用
JP2024530970A (ja) * 2020-08-18 2024-08-27 エービーエル バイオ インコーポレイテッド 抗－ｂ７－ｈ４／抗－４－１ｂｂ二重特異的抗体およびこれの用途
AU2021331076A1 (en) * 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
TW202233673A (zh) 2020-10-23 2022-09-01 美商雅雪生物治療公司 含調節免疫細胞功能之ｃｄ８抗原結合分子之融合物
CA3203721A1 (en) 2021-01-04 2022-07-07 Timothy B. Lowinger B7h4-targeted antibody-drug conjugates and methods of use thereof
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
US20240383982A1 (en) 2021-05-07 2024-11-21 Genmab A/S Pharmaceutical compositions comprising bispecific antibodies binding to b7h4 and cd3
WO2022245500A1 (en) 2021-05-19 2022-11-24 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
AU2022283467A1 (en) 2021-05-28 2023-12-07 Seagen Inc. Anthracycline antibody conjugates
CA3232806A1 (en) * 2021-09-30 2023-04-06 Seagen Inc. B7-h4 antibody-drug conjugates for the treatment of cancer
CA3238965A1 (en) 2021-12-01 2023-06-08 Kadmon Corporation, Llc B7-h4 antibodies and anti-b7-h4 antibody/il-15 fusion proteins
KR20250004952A (ko) 2022-03-17 2025-01-08 씨젠 인크. 캄프토테신 접합체
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体
CN116589580A (zh) * 2023-04-07 2023-08-15 福建医科大学 特异性靶向b7-h4的抗体及其制备方法和应用
TW202517301A (zh) 2023-10-06 2025-05-01 美商思進公司 用ｂ７－ｈ４抗體－藥物結合物治療晚期實體腫瘤之方法
TW202535940A (zh) 2023-10-24 2025-09-16 美商思進公司 化學治療化合物及使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100483A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. Anti-human b7-h4 antibodies and their uses
WO2015017600A1 (en) 2013-08-01 2015-02-05 Five Prime Therapeutics, Inc. Afucosylated anti-fgfr2iiib antibodies

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US7328387B2 (en) 2004-12-10 2008-02-05 Texas Instruments Incorporated Addressable tap domain selection circuit with selectable ⅗ pin interface
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US5672694A (en) 1995-10-24 1997-09-30 University Of Iowa Research Foundation β-sarcoglycan nucleic acid sequence, and nucleic acid probes
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20060223077A1 (en) 1997-06-06 2006-10-05 Human Genome Sciences, Inc. 207 human secreted proteins
US20030181692A1 (en) 1997-06-06 2003-09-25 Jian Ni 207 human secreted proteins
US20030060612A1 (en) 1997-10-28 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6914130B2 (en) 1998-06-17 2005-07-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
SE9804180L (sv) 1998-12-03 2000-01-24 Scania Cv Ab Anordning för ventilation av ett utrymme i ett fordon
US6962980B2 (en) 1999-09-24 2005-11-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US7888477B2 (en) 1998-12-17 2011-02-15 Corixa Corporation Ovarian cancer-associated antibodies and kits
US6468546B1 (en) 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
US20020146727A1 (en) 1999-11-30 2002-10-10 Dillon Davin C. Compositions and methods for the therapy and diagnosis of breast cancer
CA2392510A1 (en) 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
US20040142361A1 (en) 1999-11-30 2004-07-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
AU2001245308A1 (en) 2000-02-24 2001-09-03 Human Genome Sciences, Inc. 207 human secreted proteins
DE60114830T2 (de) 2000-06-28 2006-08-03 Glycofi, Inc. Verfahren zur herstellung modifizierter glycoproteine
JP2004502414A (ja) 2000-06-30 2004-01-29 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド Ｂ７様ポリヌクレオチド、ポリペプチドおよび抗体
AU2001283507A1 (en) 2000-07-27 2002-02-13 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
KR20040014392A (ko) 2000-08-24 2004-02-14 제넨테크, 인크. 종양의 진단 및 치료용 조성물 및 방법
KR20030029847A (ko) 2000-08-24 2003-04-16 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
EP1331266B1 (en) 2000-10-06 2017-01-04 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
EP1333032A4 (en) 2000-10-06 2005-03-16 Kyowa Hakko Kogyo Kk PROCESS FOR PURIFYING ANTIBODY
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
US20030087250A1 (en) 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US7705120B2 (en) 2001-06-21 2010-04-27 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
NZ603111A (en) 2001-08-03 2014-05-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
WO2005062788A2 (en) 2003-12-22 2005-07-14 Avalon Pharmaceuticals, Inc. Prostate specific proteins expressed in cancer and methods of use thereof
US20060099214A1 (en) 2002-06-11 2006-05-11 Reinhard Ebner Cancer-linked gene as target for chemotherapy
WO2005035724A2 (en) 2003-10-08 2005-04-21 Avalon Pharmaceuticals, Inc Cancer-linked genes as targets for chemotherapy
WO2003101400A2 (en) 2002-06-04 2003-12-11 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
WO2003076579A2 (en) 2002-03-06 2003-09-18 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
CA2799805C (en) 2002-03-19 2016-05-17 Stichting Dienst Landbouwkundig Onderzoek Optimizing glycan processing in plants
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
CA2485983A1 (en) 2002-05-15 2003-11-27 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
AU2003229293A1 (en) 2002-05-16 2003-12-02 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
EP1576111A4 (en) 2002-06-07 2006-10-18 Avalon Pharmaceuticals CANCER-ASSOCIATED GENE AS A TARGET FOR CHEMOTHERAPY
WO2007001459A2 (en) 2004-11-15 2007-01-04 Washington University Compositions and methods for modulating lymphocyte activity
EP1539218A4 (en) 2002-06-20 2007-08-22 Univ California COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY
JP2006511222A (ja) 2002-12-20 2006-04-06 アバロン ファーマシューティカルズ，インコーポレイテッド がんで発現される乳房特異的タンパク質およびその使用法
JP5425365B2 (ja) 2003-01-22 2014-02-26 グリカート バイオテクノロジー アクチェンゲゼルシャフト 増加したＦｃレセプター結合親和性およびエフェクター機能を有する抗体を作製するための融合構築物およびその使用
EP1633784B1 (en) 2003-05-09 2011-07-13 Diadexus, Inc. Ovr110 antibody compositions and methods of use
WO2004113500A2 (en) 2003-06-16 2004-12-29 The University Of Washington B7s1: an immune modulator
WO2005052121A2 (en) 2003-11-21 2005-06-09 Archemix Corp. Multivalent aptamers
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20090136490A1 (en) 2004-11-10 2009-05-28 Diadexus, Inc. Ovr110 antibody compositions and methods for use
ES2343746T3 (es) 2005-01-07 2010-08-09 Diadexus, Inc. Composiciones de anticuerpo ovr110 y metodos de uso.
US20110097330A1 (en) 2005-03-11 2011-04-28 Genentech, Inc. Novel Gene Disruptions, Compostitions and Methods Relating Thereto
US8759490B2 (en) 2005-03-24 2014-06-24 Millennium Pharamaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
EP2384767B1 (en) 2005-03-24 2016-03-09 Millennium Pharmaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
DK1866339T3 (da) 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
WO2006121991A2 (en) 2005-05-06 2006-11-16 Diadexus, Inc. Compositions and methods for detection, prognosis and treatment of breast cancer
MX2007013924A (es) 2005-05-09 2008-01-28 Glycart Biotechnology Ag Moleculas que unen antigeno que tienen regiones fc modificadas y union alterada a receptores fc.
BRPI0611766A2 (pt) 2005-06-08 2011-12-20 Dana Farber Cancer Inst Inc métodos e composições para o tratamento de infecções persistentes e cáncer por inibição da rota de morte celular programada
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
RS54271B1 (sr) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
AU2006321553B2 (en) * 2005-12-08 2012-03-08 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to O8E
US20090215084A1 (en) 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
MX2008009220A (es) 2006-01-17 2008-10-10 Biolex Therapeutics Inc Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas.
KR101516823B1 (ko) 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 안정화된 폴리펩티드 조성물
US9121853B2 (en) 2006-03-20 2015-09-01 Mayo Foundation For Medical Education And Research B7-H4 expression on tumor vasculature
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2007124361A2 (en) 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
WO2008051919A2 (en) 2006-10-23 2008-05-02 Acco Brands Usa Llc Security apparatus
EP2104513B1 (en) 2006-11-27 2015-05-20 diaDexus, Inc. Ovr110 antibody compositions and methods of use
US8907065B2 (en) 2006-12-15 2014-12-09 Ablynx N.V. Polypeptides that modulate the interaction between cells of the immune system
US20080206235A1 (en) 2006-12-27 2008-08-28 Johns Hopkins University Compositions and methods for stimulating an immune response
WO2008154333A2 (en) 2007-06-08 2008-12-18 Asuragen, Inc. Mir-34 regulated genes and pathways as targets for therapeutic intervention
ES2776406T3 (es) 2007-07-12 2020-07-30 Gitr Inc Terapias de combinación que emplean moléculas de enlazamiento a GITR
TWI595005B (zh) 2007-08-21 2017-08-11 安健股份有限公司 人類ｃ－ｆｍｓ抗原結合蛋白質
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3753947A1 (en) 2007-09-14 2020-12-23 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
TW200938224A (en) 2007-11-30 2009-09-16 Medarex Inc Anti-B7H4 monoclonal antibody-drug conjugate and methods of use
WO2009111315A2 (en) 2008-02-29 2009-09-11 Mayo Foundation For Medical Education And Research Methods for reducing granulomatous inflammation
US8840889B2 (en) 2009-08-13 2014-09-23 The Johns Hopkins University Methods of modulating immune function
AU2010286351A1 (en) 2009-08-31 2012-03-15 Amplimmune, Inc. B7-H4 fusion proteins and methods of use thereof
US8709424B2 (en) 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
CA2789071C (en) 2010-03-05 2018-03-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
KR20200044999A (ko) 2010-05-04 2020-04-29 파이브 프라임 테라퓨틱스, 인크. Ｃｓｆ1ｒ에 결합하는 항체들
US20120014947A1 (en) 2010-07-16 2012-01-19 The University Of Chicago Methods and compositions to reduce liver damage associated with conditions or therapies that affect the immune system
JP6266343B2 (ja) 2010-07-16 2018-01-24 アディマブ， エルエルシー 抗体ライブラリー
KR20160044598A (ko) 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
WO2012145568A1 (en) 2011-04-21 2012-10-26 Albert Einstein College Of Medicine Of Yeshiva University Antibodies to human b7x for treatment of metastatic cancer
EP2703486B1 (en) 2011-04-25 2018-03-07 Daiichi Sankyo Company, Limited Anti-b7-h3 antibody
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
WO2013025779A1 (en) * 2011-08-15 2013-02-21 Amplimmune, Inc. Anti-b7-h4 antibodies and their uses
WO2013067492A1 (en) 2011-11-03 2013-05-10 The Trustees Of The University Of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
KR20150100715A (ko) 2012-12-21 2015-09-02 앰플리뮨, 인크. 항-h7cr 항체
KR20150127199A (ko) 2013-03-14 2015-11-16 제넨테크, 인크. 항-b7-h4 항체 및 면역접합체
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
US20160146806A1 (en) 2013-05-17 2016-05-26 Amplimmune, Inc. Receptors for b7-h4
AU2014296887A1 (en) 2013-08-02 2016-01-28 Aduro Biotech Holdings, Europe B.V. Combining CD27 agonists and immune checkpoint inhibition for immune stimulation
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
JP2016540042A (ja) 2013-11-05 2016-12-22 コグネート バイオサービシズ， インコーポレイテッド がんを処置するためのチェックポイント阻害剤および治療薬の組合せ
WO2015094782A1 (en) 2013-12-18 2015-06-25 Albert Einstein College Of Medicine Of Yeshiva University B7x and its derivatives for treating and preventing cardiovascular disease
WO2015100219A1 (en) 2013-12-23 2015-07-02 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
CA2936244A1 (en) 2014-01-21 2015-07-30 Medimmune, Llc Compositions and methods for modulating and redirecting immune responses
CN113912723A (zh) 2014-03-24 2022-01-11 癌症研究技术有限公司 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
JP6943760B2 (ja) 2014-09-12 2021-10-06 ジェネンテック， インコーポレイテッド 抗ｂ７−ｈ４抗体及び免疫複合体
US10927410B2 (en) 2014-10-17 2021-02-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators
EP3223865A4 (en) 2014-10-31 2018-10-03 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4
EP3274369A4 (en) 2015-03-27 2018-10-17 University of Southern California Car t-cells for the treatment of b7-h4 expressing solid tumors
EP3875477A1 (en) 2015-04-17 2021-09-08 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
KR102740444B1 (ko) 2015-04-17 2024-12-10 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
CA2988604C (en) 2015-06-11 2023-05-09 Gabriel Kremmidiotis Pharmaceutical combination and uses thereof
RU2753439C2 (ru) 2015-07-23 2021-08-16 Инхибркс, Инк. Поливалетные и полиспецифичные gitr-связывающие слитые белки
SMT202100527T1 (it) 2015-07-30 2021-11-12 Macrogenics Inc Molecole di legame a pd-1 e lag-3 e loro metodi d'uso
BR112018004965A2 (pt) 2015-09-14 2018-10-09 Alpine Immune Sciences Inc domínios de superfamìlia de imunoglobulina variante ajustàvel
WO2017058754A1 (en) 2015-09-28 2017-04-06 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
BR112018008865A8 (pt) 2015-11-02 2019-02-26 Five Prime Therapeutics Inc polipeptídeos do domínio extracelular cd80 e seu uso no tratamento do câncer
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
JP6970099B2 (ja) 2016-01-28 2021-11-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ガンの処置のための方法及び医薬組成物
WO2017147368A1 (en) 2016-02-24 2017-08-31 Oncomed Pharmaceuticals, Inc. Redirecting immune responses
US20190343940A1 (en) 2016-03-04 2019-11-14 Io Biotech Aps Combination therapy against cancer
US10875919B2 (en) 2016-04-26 2020-12-29 Alector Llc Chimeric receptors and methods of use thereof
CN115350263A (zh) 2016-05-20 2022-11-18 拜尔哈文制药股份有限公司 谷氨酸调节剂与免疫疗法用以治疗癌症的用途
JP2019529418A (ja) 2016-09-16 2019-10-17 バイオノミックス リミテッド 抗体およびチェックポイント阻害剤の併用療法
US10042000B2 (en) 2016-10-13 2018-08-07 Stmicroelectronics (Grenoble 2) Sas Method and apparatus for high frequency analog-to-digital conversion
AU2017345764A1 (en) 2016-10-20 2019-05-02 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
GB201618291D0 (en) 2016-10-28 2016-12-14 Bergen Teknologioverf�Ring As Novel immunotherapeutic treatments for tumours
BR112019010349A2 (pt) 2016-11-23 2019-10-08 Bioverativ Therapeutics Inc Anticorpos anti-fixa, anti-fxz e antifxa, molécula biespecífica, ácido nulceico, composiçãofarmacêutica e uso dos anteriores
EA201991383A1 (ru) 2016-12-07 2019-12-30 Эйдженус Инк. Антитела против ctla-4 и способы их применения
KR102603681B1 (ko) 2016-12-07 2023-11-17 아게누스 인코포레이티드 항체 및 이의 사용방법
PE20200797A1 (es) 2017-08-25 2020-08-10 Five Prime Therapeutics Inc Anticuerpos que se unen especificamente a b7-h4 humana
SG11202007820QA (en) * 2018-02-21 2020-09-29 Five Prime Therapeutics Inc B7-h4 antibody dosing regimens
BR112020016986A2 (pt) 2018-02-21 2021-03-02 Five Prime Therapeutics, Inc. formulações de anticorpo contra b7-h4
CA3091801A1 (en) * 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
BR112021007134A2 (pt) 2018-10-15 2021-08-10 Five Prime Therapeutics, Inc. terapia combinada para câncer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100483A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. Anti-human b7-h4 antibodies and their uses
WO2015017600A1 (en) 2013-08-01 2015-02-05 Five Prime Therapeutics, Inc. Afucosylated anti-fgfr2iiib antibodies

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Cancer Letters，2012年，Vol.317，pp.99-105
Cell Reports，2014年，Vol.9，pp.1089-1098
DENARDA DANGAJ; ET AL，BLOCKING THE B7-H4 PATHWAY WITH NOVEL RECOMBINANT ANTIBODIES ENHANCES T CELL-以下備考，ONCOIMMUNOLOGY，2013年08月，VOL:2, NR:8，PAGE(S):E25913-1 - E25913-3，http://dx.doi.org/10.4161/onci.25913，MEDIATED ANTITUMOR RESPONSES
Monoclonal Antibodies，2014年，Vol.33, No.4，pp.270-274
ONCOIMMUNOLOGY，2013年08月，Vol.2, No.8，pp:E25913-1 - E25913-3
ONCOIMMUNOLOGY，2013年08月，VOL:2, NR:8，PAGE(S):E25913-1 - E25913-3

Also Published As

Publication number Publication date
US11306144B2 (en) 2022-04-19
CL2025002241A1 (es) 2025-10-24
TW201920279A (zh) 2019-06-01
MX2020002076A (es) 2020-03-24
EP3672990A1 (en) 2020-07-01
MX2025009210A (es) 2025-09-02
WO2019040780A1 (en) 2019-02-28
CR20200138A (es) 2020-06-14
CL2025002111A1 (es) 2025-10-24
JP2021500853A (ja) 2021-01-14
IL321706A (en) 2025-08-01
AU2018321902B2 (en) 2025-06-05
IL272274B2 (en) 2025-12-01
ECSP20020111A (es) 2020-04-22
KR20240138135A (ko) 2024-09-20
CN111094352A (zh) 2020-05-01
SG11202000387YA (en) 2020-03-30
KR102761792B1 (ko) 2025-02-04
MX2025009209A (es) 2025-09-02
JP2024042117A (ja) 2024-03-27
CA3070774A1 (en) 2019-02-28
KR20200038305A (ko) 2020-04-10
CL2020000452A1 (es) 2020-08-21
MA49950A (fr) 2020-07-01
US20190085080A1 (en) 2019-03-21
UA128472C2 (uk) 2024-07-24
US11814431B2 (en) 2023-11-14
IL272274A (en) 2020-03-31
CN111094352B (zh) 2024-10-01
TW202423980A (zh) 2024-06-16
BR112020003533A2 (pt) 2020-11-17
AU2018321902A1 (en) 2020-02-13
US20200255528A1 (en) 2020-08-13
TWI817952B (zh) 2023-10-11
IL272274B1 (en) 2025-08-01
PH12020500368A1 (en) 2021-01-25
US20240043542A1 (en) 2024-02-08
AU2025220883A1 (en) 2025-09-18
CR20250168A (es) 2025-06-20
CL2023002239A1 (es) 2024-03-08
TWI870011B (zh) 2025-01-11
CO2020001955A2 (es) 2020-04-01
CN119552248A (zh) 2025-03-04
US20230013293A1 (en) 2023-01-19
PE20200797A1 (es) 2020-08-10

Similar Documents

Publication Publication Date Title
JP7437301B2 (ja) Ｂ７－ｈ４抗体及びその使用方法
EP3558365B1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
KR102522693B1 (ko) 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체
US20240368295A1 (en) Anti-bcma antibodies and treatment methods
CA3056972A1 (en) Anti-ox40 antibody and use thereof
CN114729038A (zh) Cd39的高亲和力抗体及其用途
US20240317864A1 (en) B7-h4 antibody dosing regimens
US20210332137A1 (en) Combination therapy for cancer
CN116997357A (zh) 针对gdf-15的抗体
WO2023040940A1 (zh) Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
AU2023295521A1 (en) Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof
EA046814B1 (ru) Антитела к b7-h4 и способы их применения
WO2025137093A1 (en) Uses for attenuated il-2 immunoconjugates
HK40027698A (en) B7-h4 antibodies and methods of use thereof
HK40027698B (zh) B7-h4抗体及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240209

R150 Certificate of patent or registration of utility model

Ref document number: 7437301

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150